Prevalence and prognostic implications of the no-reflux phenomenon in patients undergoing primary percutaneous coronary intervention at a university center in a middle-income country.
Luis B Godínez-Córdova, Héctor González-Pacheco, Guering Eid-Lidt, Daniel Manzur-Sandoval, Rodrigo Gopar-Nieto, Daniel Sierra-Lara-Martínez, José L Briseño-de la Cruz, Diego Araiza-Garaygordobil, Salvador Mendoza-García, Alfredo Altamirano-Castillo, Alexandra Arias-Mendoza
{"title":"Prevalence and prognostic implications of the no-reflux phenomenon in patients undergoing primary percutaneous coronary intervention at a university center in a middle-income country.","authors":"Luis B Godínez-Córdova, Héctor González-Pacheco, Guering Eid-Lidt, Daniel Manzur-Sandoval, Rodrigo Gopar-Nieto, Daniel Sierra-Lara-Martínez, José L Briseño-de la Cruz, Diego Araiza-Garaygordobil, Salvador Mendoza-García, Alfredo Altamirano-Castillo, Alexandra Arias-Mendoza","doi":"10.24875/ACM.23000120","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the prevalence of no-reflow and the 30-day mortality in a university center in a middle-income country.</p><p><strong>Method: </strong>We analyzed 2463 patients who underwent primary PCI from January 2006 to December 2021. The outcome measure was 30-day mortality.</p><p><strong>Results: </strong>Of a total of 2463 patients, no-reflow phenomenon was found in 413 (16.8%) patients, 30-day mortality was 16.7 vs. 4.29% (p < 0.001). Patients with no-reflow were older 60 (53-69.5) vs. 59 (51-66) (p = 0.001), with a higher delay in onset of symptom to emergency department arrival 270 vs. 247 min (p = 0.001). No-reflow patients also had had fewer previous myocardial infarction, 11.6 vs. 18.4 (p = 0.001) and a Killip class > 1, 37 vs. 26% (p < 0.001). No-reflow patients were more likely to have an anterior myocardial infarction (55.4 vs. 47.8%; p = 0.005) and initial TIMI flow 0 (76 vs. 68%; p < 0.001).</p><p><strong>Conclusion: </strong>No-reflow occurred in 16.8% of STEMI patients undergoing primary PCI and was more likely with older age, delayed presentation, anterior myocardial infarction and Killip class > 1. No-reflow was associated with a higher mortality at 30-day follow-up.</p>","PeriodicalId":93885,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"94 3","pages":"331-340"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259416/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de cardiologia de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/ACM.23000120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To analyze the prevalence of no-reflow and the 30-day mortality in a university center in a middle-income country.
Method: We analyzed 2463 patients who underwent primary PCI from January 2006 to December 2021. The outcome measure was 30-day mortality.
Results: Of a total of 2463 patients, no-reflow phenomenon was found in 413 (16.8%) patients, 30-day mortality was 16.7 vs. 4.29% (p < 0.001). Patients with no-reflow were older 60 (53-69.5) vs. 59 (51-66) (p = 0.001), with a higher delay in onset of symptom to emergency department arrival 270 vs. 247 min (p = 0.001). No-reflow patients also had had fewer previous myocardial infarction, 11.6 vs. 18.4 (p = 0.001) and a Killip class > 1, 37 vs. 26% (p < 0.001). No-reflow patients were more likely to have an anterior myocardial infarction (55.4 vs. 47.8%; p = 0.005) and initial TIMI flow 0 (76 vs. 68%; p < 0.001).
Conclusion: No-reflow occurred in 16.8% of STEMI patients undergoing primary PCI and was more likely with older age, delayed presentation, anterior myocardial infarction and Killip class > 1. No-reflow was associated with a higher mortality at 30-day follow-up.